leisure time -WSS

leisure time

author：knowledge 2025-10-02 20:52:52 - browse：29

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Google and Epic fight stronger regulation of AI in health care

entertainment

WSS

Why hospitals are withdrawing from US News rankings

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

How dance can help nurses traumatized by Covid

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

There's no autism epidemic. It's an autism diagnosis epidemic

At Orexo, a ‘turning point’ for everything but digital health

knowledge

leisure time

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Sanders adds drug shortage policies to pandemic preparedness bill

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why the world’s most expensive drug might be worth the price

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Peter Hotez and the public health issue of online harassment

Medicare has a new plan to address drug shortages

Hepatitis C has a cure — but many Americans still lack access to it

AI can’t replace a physician’s gut feeling

hotspot

Steward Health Care has deal to sell doctor network to UnitedHealth

WHO calls for emergency meeting on new China virus, as cases spread

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

In early work, researchers turn to CRISPR to treat Alzheimer's

FDA's naming rule on biosimilars has undermined competition

Custom gene therapy hints at new path for rare disease treatments

entertainment

Wikipedia

hotspot

Wikipedia